Boston Scientific Executive Q&A at TD Cowen Health Care Conference, March 3, 2026
- Boston Scientific will hold a 30‑minute Q&A at TD Cowen conference March 3, 2026, with CEO Mahoney and CMO Stein.
- Boston Scientific will discuss strategy, clinical and commercial progress, and near‑term priorities, with a live webcast and replay.
- Boston Scientific reported Q4 2025 net sales of $5.286 billion, up 15.9% year‑over‑year, signaling commercial momentum.
Boston Scientific Schedules Executive Q&A at TD Cowen Conference
Boston Scientific is set to present at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026, where Chairman and Chief Executive Officer Mike Mahoney and Senior Vice President and Global Chief Medical Officer Kenneth Stein will take part in a roughly 30‑minute question‑and‑answer session. The management discussion, scheduled for about 9:10 a.m. ET, is slated to focus on strategy, recent clinical and commercial progress and near‑term priorities, the company says. A live webcast and a replay, available about an hour after the session concludes, are accessible via the company’s investor relations site.
The appearance gives Boston Scientific a platform to update investors, analysts and the medical community on advances across its broad device portfolio, which addresses cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. Company executives are expected to address how recent clinical outcomes and product launches are translating into commercial traction and how that momentum informs near‑term R&D and market priorities. The session also provides a forum for the host analyst to probe regulatory pathways, trial readouts and market access strategies for key programs.
The presentation follows an active period for the medical device maker as it continues to position itself around cost‑effective therapies and expanding clinical indications. By placing senior clinical and commercial leadership on stage together, Boston Scientific aims to link clinical evidence with commercialization plans and to signal continuity in medical and business strategy to customers and healthcare partners.
Quarterly performance context
Boston Scientific reports that net sales for the fourth quarter of 2025 total $5.286 billion, a 15.9% reported increase year‑over‑year, underscoring commercial momentum heading into the March presentation. The company frames the quarterly results as a backdrop for the conference update, linking topline growth to recent product performance and market expansion.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

